Venture capital-backed startup Theranos, the former biotechnology darling of Silicon Valley, once proposed challenging the status-quo of how blood tests are ran for millions of Americans every year. That challenge was primarily posed to the two largest blood testing incumbents in the space today, LabCorp (LH) and Quest Diagnostics (DGX) .
With Theranos drowning in federal investigations, both of these incumbents can now breathe a sight of relief, at least for now.
